Markets Maxim starts Longeveron at buy; PT $14 Maxim Group initiated coverage of Longeveron (NASDAQ:LGVN) with a “buy” rating and $14 price target. The stock closed at $6.52 on March 23. Longeveron is developing a medicinal signaling cell therapy, Lomecel-B, for... March 24, 2022